Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

For Health Care Professionals

Come see us at the HFA Symposium on 3/27 - 3/30!

 Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

THE EHL FLEXXIBILITY FACTORa

Esperoct® is an extended half-life (EHL) factor 8 treatment—that means it is designed to stay in the body longer, up to 22 hours on average in adults with hemophilia A, so it can be taken less often than standard half-life treatment.b Esperoct® can be used as prophylaxis or on demand, depending on what you and your doctor decide fits your life and your needs.

aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

bData shown are from 42 adults who received a pharmacokinetic assessment after a single dose of Esperoct® 50 IU/kg.

 Pink purse

No More Compromises

Get treatment that goes where you go with the highest temperature flexibility of available EHL products

 EHL temperature flexibility range
Tammy smiling
quotation-mark-icon.png

I can just throw it in my backpack and go and then if I need to stop and infuse, I can do that.”

– Tammy has hemophilia A and uses Esperoct®
Esperoct for women and girls of all ages with hemophilia A

Stay Protected From Bleeds

1.2 median overall bleeds per year for adults and adolescents 12 to 70 years old for 76 weeks (n=175)c

  • 0.8 median overall bleeds per year for up to 6.6 years (n=177)d

In a clinical trial of Esperoct®, 97% of all bleeds were controlled with 1 to 2 dosese

cData shown are from the main phase study of 175 previously treated males aged 12 and older with severe hemophilia A who received Esperoct® 50 IU/kg every 4 days for 76 weeks.

dMedian annualized bleeding rate shown is from the main and extension phases of the pivotal clinical trial of previously treated males aged ≥12 years with severe hemophilia A who received Esperoct® 50 IU/kg every 4 days for up to 6.6 years.

eData shown are from a study where 12 adult and adolescent PTPs with severe hemophilia chose to be treated on demand and received Esperoct® for 532 bleeding episodes.

Prep Your Medication Fast

Get back to what matters—your busy life

 Pink clock icon

Quick administration? Yes, please!

Preparing an infusion is fast:
Just ATTACH, TWIST, and MIX with MixPro®.

 

Learn to Administer Esperoct®

 Pink refrigerator icon

After reconstitution, Esperoct® can be used for up to 4 HOURS at up to 86 °F

 

OR

Stored in a refrigerator between 
36 °F and 46 °F for up to 24 HOURS

Established Safety & Efficacy You Can Trust

Esperoct® was studied in an extensive long-term clinical trial program for hemophilia A

 Health insurance icon

Studied in 1 of the largest and longest clinical trial programs with 270 previously treated patients for more than 105,000 infusion days

  • 0 blood clots and no PEG-related safety concerns
  • One previously treated patient with a high-risk genetic variation developed an inhibitor to Factor 8f 
    • Similar to the reported rate in patients with severe hemophilia A

fAn 18-year-old African American male developed an inhibitor after 93 infusion days of Esperoct®. The inhibitor rose to 13.5 Bethesda units and the patient stopped participation in the study. There was no change in efficacy, and the inhibitor eventually went away on its own (without use of immune tolerance induction therapy).

Have More Questions? 


Get Connected with Your Community

Contact a Novo Nordisk Rare Blood Community Liaison (RBCL)

Life with a bleeding disorder can bring challenges, questions, and the occasional bump in the road. That’s why Novo Nordisk goes beyond treatment to provide information, education, and resources that might help. Our Rare Blood Community Liaisons (RBCLs) are experienced, active in the hemophilia community, and ready to provide you with one-on-one support, including:

Information about Esperoct®, Novoeight®, and trial prescriptions

Bleeding disorder and lifestyle education

Updates on local events

Tools to help you manage your bleeding disorder

Contact a Novo Nordisk Rare Blood Community Liaison (RBCL)

Life with a bleeding disorder can bring challenges, questions, and the occasional bump in the road. That’s why Novo Nordisk goes beyond treatment to provide information, education, and resources that might help. Our Rare Blood Community Liaisons (RBCLs) are experienced, active in the hemophilia community, and ready to provide you with one-on-one support, including:

Information about Esperoct®, Novoeight®, and trial prescriptions

Bleeding disorder and lifestyle education

Updates on local events

Tools to help you manage your bleeding disorder

Advocacy Organizations

You have the power to advocate for yourself and become an advocate for other women and girls living with hemophilia. This community is strong and there’s a place for you in it.

Meet people who get it: 

Check out these community organizations.

HFA Blood Sisterhood

Ladybugs

NBDF Educational Resources

FAIR time for women

Foundation for Women and Girls with Blood Disorders

 Victoria and white dog
Novoeight® packge and vial

Curious about your standard half-life options?

Learn more about Novoeight®, the SHL flexibility factor made to fit your life on your terms.

Let's go
Woman and girl icon

It’s your turn

It’s time to challenge the misconception that women or girls are just “carriers" of hemophilia. Use your Self-Advocacy Guide to track symptoms and guide conversations with your doctor.

Get your guide
Show more Show less

Important Safety Information

Who should not use Esperoct®?

  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

What is the most important information I need to know about Esperoct®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What should I tell my healthcare provider before using Esperoct®?

  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®

What are the possible side effects of Esperoct®?

  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Novoeight®?

  • You should not use Novoeight® if you are allergic to factor VIII or any of the other ingredients of Novoeight® or if you are allergic to hamster proteins

What is the most important information I need to know about Novoeight®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
  • Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, Iight-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

What should I tell my healthcare provider before using Novoeight®?

  • Before taking Novoeight®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Novoeight®, which may stop Novoeight® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Novoeight® 

What are the possible side effects of Novoeight®? 

  • Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever

Please click here for Prescribing Information.

Novoeight® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Novoeight®?

Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

  • Novoeight® is not used to treat von Willebrand Disease

What is Novoeight®?

Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

  • Novoeight® is not used to treat von Willebrand Disease

Show more Show less
Show more Show less

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Esperoct®?

  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

Important Safety Information

Who should not use Esperoct®?

  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

What is the most important information I need to know about Esperoct®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What should I tell my healthcare provider before using Esperoct®?

  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®

What are the possible side effects of Esperoct®?

  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Novoeight®?

Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

  • Novoeight® is not used to treat von Willebrand Disease

What is Novoeight®?

Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

  • Novoeight® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Novoeight®?

  • You should not use Novoeight® if you are allergic to factor VIII or any of the other ingredients of Novoeight® or if you are allergic to hamster proteins

What is the most important information I need to know about Novoeight®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
  • Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, Iight-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

What should I tell my healthcare provider before using Novoeight®?

  • Before taking Novoeight®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Novoeight®, which may stop Novoeight® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Novoeight® 

What are the possible side effects of Novoeight®? 

  • Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever

Please click here for Prescribing Information.

Novoeight® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

Who should not use Novoeight®?

  • You should not use Novoeight® if you are allergic to factor VIII or any of the other ingredients of Novoeight® or if you are allergic to hamster proteins

What is the most important information I need to know about Novoeight®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
  • Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, Iight-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

What should I tell my healthcare provider before using Novoeight®?

  • Before taking Novoeight®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Novoeight®, which may stop Novoeight® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Novoeight® 

What are the possible side effects of Novoeight®? 

  • Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever

Please click here for Prescribing Information.

Novoeight® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

Who should not use Esperoct®?

  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

What is the most important information I need to know about Esperoct®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What should I tell my healthcare provider before using Esperoct®?

  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®

What are the possible side effects of Esperoct®?

  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Novoeight®?

  • You should not use Novoeight® if you are allergic to factor VIII or any of the other ingredients of Novoeight® or if you are allergic to hamster proteins

What is the most important information I need to know about Novoeight®?

  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
  • Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, Iight-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

What should I tell my healthcare provider before using Novoeight®?

  • Before taking Novoeight®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Novoeight®, which may stop Novoeight® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Novoeight® 

What are the possible side effects of Novoeight®? 

  • Common side effects of Novoeight® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever

Please click here for Prescribing Information.

Novoeight® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Novoeight®?

Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

  • Novoeight® is not used to treat von Willebrand Disease

What is Novoeight®?

Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

  • Novoeight® is not used to treat von Willebrand Disease

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Esperoct®, MixPro®, and Novoeight® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

© 2025 Novo Nordisk All rights reserved. US24ESP00079 March 2025

 Caution icon

You are about to leave Esperoct.com, a Novo Nordisk website

Leave Esperoct.com
Caution icon

You are about to leave Esperoct.com, a Novo Nordisk website

Novo Nordisk is not responsible for the content of the site you are about to visit.

Leave Esperoct.com
Access Resources